Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study
Open Access
- 26 September 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Orphanet Journal of Rare Diseases
- Vol. 7 (1), 73
- https://doi.org/10.1186/1750-1172-7-73
Abstract
Background: Enzyme replacement therapy (ERT) in adults with Pompe disease, a progressive neuromuscular disorder, is of promising but variable efficacy. We investigated whether it alters the course of disease, and also identified potential prognostic factors. Methods: Patients in this open-label single-center study were treated biweekly with 20 mg/kg alglucosidase alfa. Muscle strength, muscle function, and pulmonary function were assessed every 3–6 months and analyzed using repeated-measures ANOVA. Results: Sixty-nine patients (median age 52.1 years) were followed for a median of 23 months. Muscle strength increased after start of ERT (manual muscle testing 1.4 percentage points per year (pp/y); hand-held dynamometry 4.0 pp/y; both p < 0.001). Forced vital capacity (FVC) remained stable when measured in upright, but declined in supine position (−1.1 pp/y; p = 0.03). Muscle function did not improve in all patients (quick motor function test 0.7 pp/y; p = 0.14), but increased significantly in wheelchair-independent patients and those with mild and moderate muscle weakness. Relative to the pre-treatment period (49 patients with 14 months pre-ERT and 22 months ERT median follow-up), ERT affected muscle strength positively (manual muscle testing +3.3 pp/y, p < 0.001 and hand-held dynamometry +7.9 pp/y, p < 0.001). Its effect on upright FVC was +1.8 pp/y (p = 0.08) and on supine FVC +0.8 (p = 0.38). Favorable prognostic factors were female gender for muscle strength, and younger age and better clinical status for supine FVC. Conclusions: We conclude that ERT positively alters the natural course of Pompe disease in adult patients; muscle strength increased and upright FVC stabilized. Functional outcome is probably best when ERT intervention is timely.Keywords
This publication has 42 references indexed in Scilit:
- 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapyJournal of Inherited Metabolic Disease, 2012
- The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patientsJournal of Inherited Metabolic Disease, 2011
- Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe diseaseNeuromuscular Disorders, 2011
- Long‐term observational, non‐randomized study of enzyme replacement therapy in late‐onset glycogenosis type IIJournal of Inherited Metabolic Disease, 2010
- Enzyme analysis for Pompe disease in leukocytes; superior results with natural substrate compared with artificial substratesJournal of Inherited Metabolic Disease, 2009
- Clinical features of late‐onset Pompe disease: A prospective cohort studyMuscle & Nerve, 2008
- Late onset Pompe disease: Clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patientsNeuromuscular Disorders, 2007
- Chinese hamster ovary cell-derived recombinant human acid α-glucosidase in infantile-onset Pompe diseaseThe Journal of Pediatrics, 2006
- Hand-held myometry: reference values.Journal of Neurology, Neurosurgery & Psychiatry, 1991
- Predicted normal values for maximal respiratory pressures in caucasian adults and children.Thorax, 1984